| |
|
|
|
|
|
 |
| |
|
ºñ¾Æ½ºÆÇ¾× VIASPAN IRRIGA.SOL.[Adenosine , Allopurinol , Glutathione , Lactobionic acid , Pentafraction , Raffinose 5H2O]
|
|
Àü¹®ÀǾàǰ | »èÁ¦
|
|
¼öÀÔÀǾàǰ
|
| |
 |
¾Ë¸²: |
µå·°ÀÎÆ÷¿¡¼´Â ÀǾàǰ ÀÎÅÍ³Ý ÆÇ¸Å¸¦ ÇÏÁö ¾Ê½À´Ï´Ù. |
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
À¯·áȸ¿ø °áÀç½Ã¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸¸¦
ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
À¯·áÁ¤º¸¸ñ·ÏÀº Àü¹®È¸¿øÀ¸·Î
·Î±×ÀÎ ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
|
|
|
 | Çã°¡Á¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå »óÇÑ±Ý¾× |
645400460[E00210361]
[º¸ÇèÄڵ忡 µû¸¥ ¾àǰ±âº»Á¤º¸ Á÷Á¢Á¶È¸]
\0 ¿ø/1l(2007.11.15)(ÇöÀç¾à°¡)
\266,325 ¿ø/1l(2002.07.01)(º¯°æÀü¾à°¡)
[»óº´ÄÚµåÁ¶È¸]
[Áúº´ÄÚµåÁ¶È¸]
|
| ºü¸¥Á¶È¸ |
|
| Á¦Ç°¼º»ó |
¹«»ö ¶Ç´Â ¹ÌȲ»öÀÇ Æú¸®¿°Èºñ´Ò(PVC) ¿ë±â¿¡ µé¾îÀÖ´Â ´ãȲ»ö-Ȳ»öÀÇ ¾× [Á¦ÇüÁ¤º¸ È®ÀÎ] |
| Æ÷À塤À¯Åë´ÜÀ§ |
1IRRIGA.SOL |
| Æ÷À塤ÄÚµå´ÜÀ§ |
| ¾àǰ±Ô°Ý |
´ÜÀ§ |
Æ÷ÀåÇüÅ |
´ëÇ¥ÄÚµå |
Ç¥ÁØÄÚµå |
ºñ°í |
| 1¸®ÅÍ |
1 °³ |
º´ |
8806454004609 |
8806454004616 |
|
|
| Çã°¡»çÇ× ¿ø¹®Á¶È¸ |
[Çã°¡»çÇ× ¿ø¹®Á¶È¸]
|
| È¿´ÉÈ¿°ú |
[ÀûÀÀÁõ º° °Ë»ö]
½ÅÀå, °£, ÃéÀåµîÀÇ Àå±âÀ̽Ľà ÀûÃâÀå±âÀÇ °ü·ù ¹× ³Ãº¸Á¸
|
| ¿ë¹ý¿ë·® |
* Àý´ë ÀÓÀǺ¹¿ëÇÏÁö ¸¶½Ã°í ¹Ýµå½Ã ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇϽñ⠹ٶø´Ï´Ù.
[󹿾à¾î]
[ÁÖ¼ººÐÄÚµå:326400BIS ¿¡ µû¸¥ ½É»çÁöħ¿¶÷]
¿ë¾×À» ¾óÀ½¿¡¼ 2-6¡É·Î ³Ã°¢ÇÏ°í »ç¿ëÀü °ÑÆ÷ÀåÀ» ¹þ±â°í ¿ë±â¸¦ È®ÀÎÇÏ¿© »õ¸é ¿ë±â¸¦ Æó±âÇÑ´Ù. °ÑÆ÷Àå Á¦°ÅÈÄ À°¾È °Ë»ç¸¦ ÇàÇÏ¿© ÀÔÀÚ, ħÀü ¶Ç´Â ¿À¿°ÀÌ È®ÀÎµÇ¸é »ç¿ëÇÏÁö ¸»¾Æ¾ß ÇÑ´Ù. À°¾È°Ë»ç¸¦ Åë°úÇÑ ¿ë±â´Â »ç¿ë½Ã in-line Pall Blood Transfusion Filter(No. SQ4OS)·Î ¿©°úÇÏ¿©¾ß ÇÑ´Ù. ÀÌ ÇÊÅ͸¸À» »ç¿ëÇÏ´Â °ÍÀÌ ÃßõµÈ´Ù.
»ç¿ëÇϱâ ÀÛÀü, ÃÖÁ¾ ¿ë¾×À» ¸¸µé±â À§ÇØ Æä´Ï½Ç¸° G 200,000EKSDNL, regular insulin 40´ÜÀ§, µ¦»ç¸ÞŸ¼Õ 16§·À» ¹«±ÕÀûÀ¸·Î ÷°¡ÇÑ´Ù.
ºñ¾Æ½ºÆÇ ¼ººÐÁßÀÇ ÇϳªÀÎ ±Û·çŸġ¿ÂÀº ÀúÀ嵿¾È »êȵȴÙ. ÇÊ¿äÇϸé, ±Û·çŸġ¿Â 0.922 g/L(3mmole/L)À» »ç¿ë Á÷Àü¿¡ ÷°¡ÇÒ ¼ö ÀÖ´Ù.
ÇÊÅÍÀÇ Ãⱸ port¿¡¼ º¸È£ ¸¶°³¸¦ Á¦°ÅÇϰí Åõ¿©¼¼Æ®ÀÇ spike¸¦ port¿¡ ºñƲ¾î »ðÀÔÇÑ ÈÄ Åõ¿©¼¼Æ®ÀÇ Áμ踦 ¿¬´Ù. "Delievery set port"¶ó°í Ç¥½ÃµÈ ¿ë±â port·ÎºÎÅÍ ³ª¼±Çü ¸¶°³(twist-off plug)¸¦ Á¦°ÅÇÑ´Ù. ÇÊÅÍ spike·ÎºÎÅÍ ±ä º¸È£¸¶°³¸¦ Á¦°ÅÇÑ ÈÄ ¿ë±âÀÇ "delievery set port"·Î ºñƲ¾î »ðÀÔÇÑ´Ù. Åõ¿©¼¼Æ®´Â ¼öÁ÷À¸·Î À¯ÁöÇϰí ÇÊÅÍ¿Í Åõ¿©¼¼Æ®¸¦ ä¿ì±â À§ÇØ ¿ë±â¸¦ ¾ÐÂøÇÑ ÈÄ Áμ踦 Á¶ÀδÙ.
Àå±â¿¡ ¿¬°áÇϱâ Àü¿¡, ¿ë±â´Â ÀûÀýÈ÷ ³ôÀº À§Ä¡¿¡ ¸Å´Þ¾Æ °ü·ùµ¿¾È À¯Ãô¼Óµµ°¡ ÃÖ¼ÒÇÑ 30§¢/ºÐÀÌ µÇµµ·Ï ÇÏ¿©¾ß ÇÑ´Ù. °ü·ù ½ÃÀÛÀ» À§ÇØ Áμ踦 ¿¾î Àå±â°¡ ±ÕÀÏÇÏ°Ô ¿¯Àº »öÀ» ¶ì°í À¯Ãô¾×ÀÌ ºñ±³Àû ¸¼¾ÆÁú ¶§±îÁö °è¼ÓµÇ¾î¾ß ÇÑ´Ù. ÇÊÅÍ´Â Àç»ç¿ëÇØ¼´Â ¾ÈµÈ´Ù.
(ÃÖ¼Ò Ãßõ ¿ë·®)
»ýü³» ´ëµ¿¸Æ °ü·ù½Ã
- ¼ºÀÎ : 2-4L
- À¯¾Æ : 50§¢/§¸
ÃéÀå ¶Ç´Â ½ÅÀå - ¼ºÀÎ : 300 - 500§¢
- À¯¾Æ : 150 - 250§¢
Àå±â¸¦ ´ã°í ÀÖ´Â ¿ë±â¿¡ Ãß°¡·Î ¿ë¾×À» °¡ÇÑ ÈÄ ¿ë±â¸¦ ¹«±Õ»óÅ¿¡¼ ºÀÇÑ´Ù. Àå±âº¸Á¸ ¿ë±â´Â ´Ü¿ÀÌ ÀßµÈ ¿î¹Ý¿ë±â ³»¿¡ °£¼öÇØ¾ß ÇÑ´Ù. ¾óÀ½Àº Àå±âº¸Á¸¿ë±â¸¦ ¿¡¿ö½Îµµ·Ï ÇÏ¿© »ç¿ëÇϵÇ, Àå±â¿Í Á÷Á¢ Á¢ÃËÇØ¼´Â ¾ÈµÇ¹Ç·Î Àå±âº¸Á¸¿ë±â ³»¿¡ ³Ö¾î¼´Â ¾ÈµÈ´Ù. °£¿¡ ¿ë¾×ÀÌ ÀÜ·ùÇÏ´Â °ÍÀ» ÃÖ¼ÒÈÇϱâ À§Çؼ ¹®ÇÕ Á÷Àü¿¡ °£ ¹®¸ÆÀ¸·Î À¯´çó¸®ÇÑ ¸µ°Å¾×(lactated Ringer) 1¸®Å͸¦ °ü·ù½ÃŲ´Ù.
|
| ÁÖ¿ä¾à¹° »óÈ£ÀÛ¿ë |
[Á¶È¸]
|
| ±Ý±â |
Áö½Ã´ë·Î »ç¿ëÇÏ¿´À» ¶§, ¾Ë·ÁÁø ±Ý±â»çÇ×Àº ¾ø´Ù. |
| ÀÌ»ó¹ÝÀÀ |
- ȯÀÚÀÇ Ç÷°ü¹®ÇÕÁμ踦 Ç®±âÀü ´Ü±â°£(1-3½Ã°£)¾È¿¡ Àå±â¸¦ »õ·Î¿î ¿ë¾×À¸·Î Àç°ü·ùÇϰųª ¿ë¾×ÀÌ ºÎÀûÀýÇÏ°Ô °ü·ù Á¦°ÅµÈ °æ¿ì¿¡´Â ¼¸Æ¼º ºÎÁ¤¸Æ°ú °°Àº ½ÉÇ÷°ü°è ÇÕº´ÁõÀÌ º¸°íµÈ ¹Ù ÀÖ´Ù.
- °£ÀÌ½Ä º¸Á¸ »ç¿ë½Ã °£±â´Éº¯È, »ç¸ÁÀ» Æ÷ÇÔÇÑ ³ª»Û °á°ú, °æ¹ÌÇÑ °ÅºÎÁõ»óÀÌ Àְųª ¾øÀÌ °£¿¡ ÇãÇ÷¼º ¼Õ»ó¿¡ ´ëÇÑ ¸î°¡Áö º¸°í°¡ ÀÖ¾úÁö¸¸ ºñ¾Æ½ºÆÇ°úÀÇ °ü·Ã¼ºÀº ¾Ë·ÁÁ® ÀÖÁö ¾Ê´Ù.
|
| Off-label Usage |
[Á¶È¸]
|
| Related FDA Approved Drug |
±âÁØ ¼ººÐ: GLUTATHIONEBSS PLUS (CALCIUM CHLORIDE; DEXTROSE; GLUTATHIONE DISULFIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE)
ENDOSOL EXTRA (CALCIUM CHLORIDE; DEXTROSE; GLUTATHIONE DISULFIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE)
NAVSTEL (CALCIUM CHLORIDE; DEXTROSE; GLUTATHIONE DISULFIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE)
±âÁØ ¼ººÐ: ALLOPURINOLALLOPURINOL (ALLOPURINOL)
ALLOPURINOL SODIUM (ALLOPURINOL SODIUM)
ALOPRIM (ALLOPURINOL SODIUM)
LOPURIN (ALLOPURINOL)
ZYLOPRIM (ALLOPURINOL)
±âÁØ ¼ººÐ: ADENOSINEADENOCARD (ADENOSINE)
ADENOSCAN (ADENOSINE)
ADENOSINE (ADENOSINE)
|
|
|
 | Á¤º¸¿ä¾à |
|
|
|
µå·°ÀÎÆ÷ ÀǾàǰ ¿ä¾à/»ó¼¼Á¤º¸
|
|
 | ÄÚµå ¹× ºÐ·ùÁ¤º¸ |
|
|
| |
|
 | Á¦Ç°Á¤º¸ |
|
|
|
|
 | º¹¾àÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| LACTmed ¹Ù·Î°¡±â |
[¹Ù·Î°¡±â]
|
| ¾à¸®ÀÛ¿ë |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º¹¾àÁöµµ |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| ÀӺο¡´ëÇÑÅõ¿© |
| * |
ÀüüÀӽŠ±â°£º°·Î ¿©·¯µî±ÞÀÌ Á¸ÀçÇÒ ¼ö ÀÖÀ¸¸ç °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ º¸¿©Áý´Ï´Ù. ´Ü, º¹ÇÕÁ¦ÀÇ °æ¿ì ¸ðµç º¹ÇÕÁ¦¼ººÐ¿¡ ´ëÇÑ ÀÓºÎÅõ¿©µî±ÞÀÌ Ç¥½ÃµÈ°ÍÀº Àý´ë ¾Æ´Ï¸ç Ç¥½ÃµÈ°ÍÁß¿¡ °¡Àå À§Çèµµ°¡ ³ôÀº Á¤º¸¸¸ ³ªÅ¸³³´Ï´Ù.
|
|
|   |
 FDA : Cµî±Þ
|
|
| * |
»ó±â ÀÓºÎÅõ¿©¿¡ ´ëÇÑ Á¤º¸´Â Àü»êó¸® µÇ¸é¼ ÀÔ·Â ¿À·ù °¡´É¼ºÀÌ Á¸ÀçÇÕ´Ï´Ù. ¿À·ù °¡´É¼ºÀ» ÃÖ¼ÒÈÇϱâ À§ÇÏ¿© ¸¹Àº ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖÀ¸³ª, ±× Á¤È®¼º¿¡ ´ëÇÏ¿© È®½ÅÀ» µå¸± ¼ö ¾ø½À´Ï´Ù. ÀÌ¿¡ ´ëÇØ ȸ»ç´Â Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù.
|
| * |
¹Ýµå½Ã °ø½Å·Â ÀÖ´Â ¹®ÇåÀ» ´Ù½Ã Çѹø Âü°í ÇϽñ⠹ٶó¸ç ÀÇ»ç ¶Ç´Â ¾à»çÀÇ ÆÇ´Ü¿¡ µû¶ó Åõ¿©¿©ºÎ°¡ °áÁ¤µÇ¾î¾ß ÇÕ´Ï´Ù.
|
|
|
| Pharmacokinetics |
À¯·áÁ¤º¸ÀÔ´Ï´Ù.
|
| º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸ |
[º´¿ë±Ý±â ¹× ¿¬·É´ë±Ý±â ±Ù°ÅÁ¶È¸]
|
| º¸°ü»ó ÁÖÀÇ |
|
| Á¶Á¦½Ã ÁÖÀÇ |
|
|
|
 | ½É»çÁ¤º¸ |
|
|
|
|
 | ÇмúÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| DUR (ÀǾàǰ»ç¿ëÆò°¡) |
º´¿ë±Ý±â :
°í½ÃµÈ º´¿ë±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[»óÈ£ÀÛ¿ë/º´¿ë±Ý±â°Ë»ö]
¿¬·É´ë±Ý±â :
°í½ÃµÈ ¿¬·É±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[¿¬·É´ë±Ý±â»ó¼¼°Ë»ö]
|
| µ¶¼ºÁ¤º¸ |
Adenosine¿¡ ´ëÇÑ µ¶¼ºÁ¤º¸ : Á¤º¸º¸±â
Allopurinol¿¡ ´ëÇÑ µ¶¼ºÁ¤º¸ : Á¤º¸º¸±â
Ãâó: ±¹¸³µ¶¼º°úÇпø µ¶¼º¹°ÁúÁ¤º¸DB : http://www.nitr.go.kr/nitr/contents/m134200/view.do |
| Mechanism of Action |
Adenosine¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Adenosine slows conduction time through the A-V node, can interrupt the reentry pathways through the A-V node, and can restore normal sinus rhythm in patients with paroxysmal supraventricular tachycardia (PSVT), including PSVT associated with Wolff-Parkinson-White Syndrome.
Allopurinol¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Allopurinol inhibits the enzyme xanthine oxidase, blocking the conversion of the oxypurines hypoxanthine and xanthine to uric acid. Elevated concentrations of oxypurine and oxypurine inhibition of xanthine oxidase through negative feedback results in a decrease in the concentrations of uric acid in the blood and urine. Allopurinol also facilitates the incorporation of hypoxanthine and xanthine into DNA and RNA, resulting in further reductions of serum uric acid concentrations.
Glutathione¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Glutathione (GSH) participates in leukotriene synthesis and is a cofactor for the enzyme glutathione peroxidase. It is also important as a hydrophilic molecule that is added to lipophilic toxins and waste in the liver during biotransformation before they can become part of the bile. Glutathione is also needed for the detoxification of methylglyoxal, a toxin produced as a by-product of metabolism. This detoxification reaction is carried out by the glyoxalase system. Glyoxalase I catalyzes the conversion of methylglyoxal and reduced glutathione to S-D-Lactoyl-glutathione. Glyoxalase II catalyzes the conversion of S-D-Lactoyl Glutathione to Reduced Glutathione and D-lactate. GSH is known as a cofactor in both conjugation reactions and reduction reactions, catalyzed by glutathione S-transferase enzymes in cytosol, microsomes, and mitochondria. However, it is capable of participating in non-enzymatic conjugation with some chemicals, as it is hypothesized to do to a significant extent with n-acetyl-p-benzoquinone imine (NAPQI), the reactive cytochrome P450 reactive metabolite formed by toxic overdose of acetaminophen. Glutathione in this capacity binds to NAPQI as a suicide substrate and in the process detoxifies it, taking the place of cellular protein sulfhydryl groups which would otherwise be toxically adducted. The preferred medical treatment to an overdose of this nature, whose efficacy has been consistently supported in literature, is the administration (usually in atomized form) of N-acetylcysteine, which is used by cells to replace spent GSSG and allow a usable GSH pool.
|
| Pharmacology |
Adenosine¿¡ ´ëÇÑ Pharmacology Á¤º¸ Adenosine is an endogenous nucleoside occurring in all cells of the body and is not chemically related to other antiarrhythmic drugs. Adenosine is indicated for the conversion to sinus rhythm of paroxysmal supraventricular tachycardia (PSVT), including that associated with accessory bypass tracts (Wolff-Parkinson-White Syndrome). Adenosine is antagonized competitively by methylxanthines such as caffeine and theophylline, and potentiated by blockers of nucleoside transport such as dipyridamole. Adenosine is not blocked by atropine.
Allopurinol¿¡ ´ëÇÑ Pharmacology Á¤º¸ Allopurinol, a structural analog of the natural purine base hypoxanthine, is used to prevent gout and renal calculi due to either uric acid or calcium oxalate and to treat uric acid nephropathy, hyperuricemia, and some solid tumors.
Glutathione¿¡ ´ëÇÑ Pharmacology Á¤º¸ Not Available
|
| Metabolism |
Adenosine¿¡ ´ëÇÑ Metabolism Á¤º¸ # Phase_1_Metabolizing_Enzyme:Adenosine deaminaseAdenosine kinase
Glutathione¿¡ ´ëÇÑ Metabolism Á¤º¸ # Phase_1_Metabolizing_Enzyme:Glutathione S-transferase A2Glutathione S-transferase A1Cytochrome P450 2E1 (CYP2E1)
|
| Protein Binding |
Allopurinol¿¡ ´ëÇÑ ´Ü¹é°áÇÕ Á¤º¸ Negligible
|
| Half-life |
Adenosine¿¡ ´ëÇÑ ¹Ý°¨±â Á¤º¸ Less than 10 secs
Allopurinol¿¡ ´ëÇÑ ¹Ý°¨±â Á¤º¸ 1-2 hours
|
| Absorption |
Adenosine¿¡ ´ëÇÑ Absorption Á¤º¸ Not Available
Allopurinol¿¡ ´ëÇÑ Absorption Á¤º¸ Approximately 90% absorbed from the gastrointestinal tract.
Glutathione¿¡ ´ëÇÑ Absorption Á¤º¸ Research suggests that glutathione is not orally bioactive, and that very little of oral glutathione tablets or capsules is actually absorbed by the body.
|
| Pharmacokinetics |
PentafractionÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
- ¹è¼³ ¹Ý°¨±â : 8-12 ½Ã°£
- ¼Ò½Ç : ´¢¹è¼³
°íºÐÀÚ´Â ¥á-amylase¿¡ ÀÇÇØ ¼¼È÷ ÀúºÐÀÚȵȴÙ.
AllopurinolÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
- ÀÛ¿ë¹ßÇö½Ã°£ : 2-3ÀÏ
- ÃÖ´ëÈ¿°ú ¹ßÇö½Ã°£ : 7-10ÀÏ
- ÀÛ¿ëÁö¼Ó½Ã°£ : 6ÀÏ
- Èí¼ö :
- °æ±¸ : 80-90% À§Àå°üÀ¸·ÎºÎÅÍ Èí¼ö
- Á÷Àå : ¾à 5%Èí¼ö
- »ýü³»ÀÌ¿ë·ü : 80-90%
- ºÐÆ÷ :
- ºÐÆ÷¿ëÀû : 1.6 L/kg
- À¯ÁóºÐºñ
- ´Ü¹é°áÇÕ : 1%ÀÌÇÏ
- ´ë»ç : 75%°¡ Ȱ¼º ´ë»çüÀÎ oxypurinol·Î ´ë»ç
- ¹Ý°¨±â :
- parent drug : 1-3 ½Ã°£
- oxypurinol : 18-30 ½Ã°£
- Ç÷ÁßÃÖ°í³óµµ µµ´Þ½Ã°£ : 80-120ºÐ
- ¼Ò½Ç : 80%´Â ½Å¹è¼³ (8-12% ¹Ìº¯Èü, 45-65% oxypurinol), 10-20%´Â ´ëº¯À» ÅëÇØ ¹è¼³µÊ
AdenosineÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
- È¿°ú¹ßÇö½Ã°£ : ÀÓ»óÈ¿°ú´Â ¸Å¿ì ºü¸£°Ô ³ªÅ¸³²
- ÀÛ¿ëÁö¼Ó½Ã°£ : ¸Å¿ì ªÀ½
- ´ë»ç : Ç÷¾×°ú Á¶Á÷¿¡¼ inosineÀ¸·Î ´ë»çµÈ ÈÄ adenosine monophosphate (AMP)¿Í hypoxanthineÀ¸·Î ´ë»çµÊ
- ¹Ý°¨±â : 10ÃÊÀ̳», ºÎÀÛ¿ëµµ ´ëºÎºÐ ºü¸£°Ô »ç¶óÁü
|
| Biotransformation |
Adenosine¿¡ ´ëÇÑ Biotransformation Á¤º¸ Intracellular adenosine is rapidly metabolized either via phosphorylation to adenosine monophosphate by adenosine kinase, or via deamination to inosine by adenosine deaminase in the cytosol.
Allopurinol¿¡ ´ëÇÑ Biotransformation Á¤º¸ Hepatic
Glutathione¿¡ ´ëÇÑ Biotransformation Á¤º¸ Not Available
|
| Toxicity |
Adenosine¿¡ ´ëÇÑ Toxicity Á¤º¸ Not Available
Allopurinol¿¡ ´ëÇÑ Toxicity Á¤º¸ LD50=214 mg/kg (in mice)
Glutathione¿¡ ´ëÇÑ Toxicity Á¤º¸ ORL-MUS LD50 5000 mg/kg, IPR-MUS LD50 4020 mg/kg, SCU-MUS LD50 5000 mg/kg, IVN-RBT LD50 > 2000 mg/kg, IMS-MUS LD50 4000 mg/kg
|
| Drug Interactions |
Adenosine¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Aminophylline This xanthine decreases the effect of adenosineDipyridamole Dipyridamole increases the effect/toxicity of adenosineDyphylline This xanthine decreases the effect of adenosineTheophylline This xanthine decreases the effect of adenosineDyphylline This xanthine decreases the effect of adenosineOxtriphylline This xanthine decreases the effect of adenosineTheophylline This xanthine decreases the effect of adenosine
Allopurinol¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Anisindione Allopurinol increases the anticoagulant effectAzathioprine Allopurinol increases the effect of thiopurineCyclosporine Allopurinol increases the effect and toxicity of cyclosporineDicumarol Allopurinol increases the anticoagulant effectWarfarin Allopurinol increases the anticoagulant effectMercaptopurine Allopurinol increases the effect of thiopurineAcenocoumarol Increases the anticoagulant effect
Glutathione¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Not Available
|
CYP450 Drug Interaction |
[CYP450 TableÁ÷Á¢Á¶È¸]
|
| Food Interaction |
Adenosine¿¡ ´ëÇÑ Food Interaction Á¤º¸ Avoid caffeine containing foods and drinks.
Allopurinol¿¡ ´ëÇÑ Food Interaction Á¤º¸ Take with a full glass of water.Take with food.Avoid alcohol.
|
| Drug Target |
[Drug Target]
|
| Description |
Adenosine¿¡ ´ëÇÑ Description Á¤º¸ A nucleoside that is composed of adenine and d-ribose. Adenosine or adenosine derivatives play many important biological roles in addition to being components of DNA and RNA. Adenosine itself is a neurotransmitter. [PubChem]
Allopurinol¿¡ ´ëÇÑ Description Á¤º¸ A xanthine oxidase inhibitor that decreases uric acid production. It also acts as an antimetabolite on some simpler organisms. [PubChem]
Glutathione¿¡ ´ëÇÑ Description Á¤º¸ A tripeptide with many roles in cells. It conjugates to drugs to make them more soluble for excretion, is a cofactor for some enzymes, is involved in protein disulfide bond rearrangement and reduces peroxides. [PubChem]
|
| Dosage Form |
Adenosine¿¡ ´ëÇÑ Dosage_Form Á¤º¸ Liquid IntravenousSolution Intravenous
Allopurinol¿¡ ´ëÇÑ Dosage_Form Á¤º¸ Tablet Oral
Glutathione¿¡ ´ëÇÑ Dosage_Form Á¤º¸ Not Available
|
| Drug Category |
Adenosine¿¡ ´ëÇÑ Drug_Category Á¤º¸ AnalgesicsAnti-Arrhythmia AgentsAntiarrhythmic AgentsCardiac drugsVasodilator Agents
Allopurinol¿¡ ´ëÇÑ Drug_Category Á¤º¸ AntimetabolitesEnzyme InhibitorsEnzyme Inhibitors AntimetabolitesFree Radical ScavengersGout Suppressants
Glutathione¿¡ ´ëÇÑ Drug_Category Á¤º¸ Dietary supplementMicronutrient
|
| Smiles String Canonical |
Adenosine¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ NC1=C2N=CN(C3OC(CO)C(O)C3O)C2=NC=N1
Allopurinol¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ O=C1N=CN=C2NNC=C12
Glutathione¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ NC(CCC(=O)NC(CS)C(=O)NCC(O)=O)C(O)=O
|
| Smiles String Isomeric |
Adenosine¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ NC1=C2N=CN([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)C2=NC=N1
Allopurinol¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ O=C1N=CN=C2NNC=C12
Glutathione¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ N[C@@H](CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O)C(O)=O
|
| InChI Identifier |
Adenosine¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C10H13N5O4/c11-8-5-9(13-2-12-8)15(3-14-5)10-7(18)6(17)4(1-16)19-10/h2-4,6-7,10,16-18H,1H2,(H2,11,12,13)/t4-,6-,7-,10-/m1/s1/f/h11H2
Allopurinol¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C5H4N4O/c10-5-3-1-8-9-4(3)6-2-7-5/h1-2H,(H2,6,7,8,9,10)/f/h8-9H
Glutathione¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C10H17N3O6S/c11-5(10(18)19)1-2-7(14)13-6(4-20)9(17)12-3-8(15)16/h5-6,20H,1-4,11H2,(H,12,17)(H,13,14)(H,15,16)(H,18,19)/t5-,6-/m0/s1/f/h12-13,15,18H
|
| Chemical IUPAC Name |
Adenosine¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ (2R,3R,4S,5R)-2-(6-aminopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
Allopurinol¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ 1,2-dihydropyrazolo[4,3-e]pyrimidin-4-one
Glutathione¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ (2S)-2-amino-5-[[(2R)-1-(carboxymethylamino)-1-oxo-3-sulfanylpropan-2-yl]amino]-5-oxopentanoic acid
|
| Drug-Induced Toxicity Related Proteins |
ADENOSINE ÀÇ Drug-Induced Toxicity Related ProteinÁ¤º¸ Replated Protein:Protein tyrosine phosphatase Drug:adenosine Toxicity:apoptosis. [¹Ù·Î°¡±â] Replated Protein:Adenosine deaminase Drug:adenosine Toxicity:ADA immunodeficiency (SCID). [¹Ù·Î°¡±â] Replated Protein:Mitogen-activated protein kinase 11 Drug:adenosine Toxicity:tactile allodynia. [¹Ù·Î°¡±â] ALLOPURINOL ÀÇ Drug-Induced Toxicity Related ProteinÁ¤º¸ Replated Protein:myeloperoxidase (MPO) Drug:allopurinol Toxicity:ischemia and reperfusion injury. [¹Ù·Î°¡±â] Replated Protein:Intercellular adhesion molecule 1 (ICAM-1) Drug:allopurinol Toxicity:damage caused by intestinal ischemia and reperfusion. [¹Ù·Î°¡±â] Replated Protein:Glycophorin A Drug:allopurinol Toxicity:Acute pure red cell aplasia. [¹Ù·Î°¡±â]
|
|
|
 | »ç¿ëÀÚÄÁÅÙÃ÷ |
|
|
|
|
|
-
ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2021-12-09
-
º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
|
|
¾Ë¸² |
»ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù. |
|
°æ°í |
µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù.
Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â
Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡±¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù.
ÀüÈ: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
|
|
¾Æ·¡ÀÇ ³»¿ëÀ» Æ÷ÇÔÇÑ Àüü µ¥ÀÌÅ͸¦ º¸½Ã·Á¸é
¿©±â·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
º´¿ë±Ý±â ¹× ƯÁ¤¿¬·É´ë ±Ý±â ¼ººÐ
[ÀǾàǰº´¿ë/¿¬·É´ë±Ý±â °í½Ã±Ù°Å·Î ¹Ù·Î°¡±â] Á¦¸ñ ¾øÀ½
2008³â 8¿ù 1ÀÏ ¾à°¡ÈÀÏ»ó 8¿ù´Þ ½Å±ÔµîÀç ¹× »èÁ¦µÇ´Â ǰ¸ñ Æ÷ÇÔÇÑ º´¿ë¿¬·É ±Ý±â ǰ¸ñ¸®½ºÆ® ±âÁØ
1. ÇöÀç °Ë»öÇÑ Á¦Ç°¿¡ ´ëÇÑ º´¿ë±Ý±â Á¦Ç° Á¸Àç¿©ºÎ ¹× °Ë»ö
ÇöÀç ÀÌÁ¦Ç°¿¡ ´ëÇÑ º´¿ë±Ý±â¿¡ ÇØ´çÇϴ û±¸Äڵ庰 Á¦Ç°³»¿ª °øÁö³»¿ëÀÌ ¾ø½À´Ï´Ù
2. ¿¬·É´ë±Ý±â Á¸Àç¿©ºÎ
ÇöÀç ÀÌÁ¦Ç°¿¡ ´ëÇÑ ¿¬·É±Ý±â¿¡ ÇØ´çÇϴ û±¸Äڵ庰 °øÁö³»¿ëÀÌ ¾ø½À´Ï´Ù
|
|
|
|